Early Ritirement YMB reminded us the that VERONA study (HR/MDS) that looked at the Ven/Aza combination did not improve OS and was essentially stopped last summer before the anticipated date of 2026. . We know from Dr. Bruedigam’s lab studies (see Nature article 2024) and presentation ASH 2024 that the combination of Ven/Aza and Imetelstat took circulating AML PDx cells from 99% to 1% in some models, and is the probable preclinical driver for the upcoming IMAGINE study. Full data on the survival of the lab animals has not yet been presented. Just something to keep in mind. bp
https://ashpublications.org/thehematolo ... dysplastic
VERONA study
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: VERONA study
Just a reinforcement of last quarters call in regards to upcoming investigator trials, as summed up by ai:::
Yes, Geron's CEO has stated that the company is actively expanding its investigator-sponsored trials (ISTs) program for Rytelo (imetelstat), particularly with U.S. clinical sites and healthcare professionals.
The company sees the IST program as a way to explore additional potential uses and answer key medical questions regarding imetelstat and the benefits of telomerase inhibition.
Yes, Geron's CEO has stated that the company is actively expanding its investigator-sponsored trials (ISTs) program for Rytelo (imetelstat), particularly with U.S. clinical sites and healthcare professionals.
The company sees the IST program as a way to explore additional potential uses and answer key medical questions regarding imetelstat and the benefits of telomerase inhibition.